U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

Substance Class
Concept
Record UNII
QU5NBP9XL3
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CORONAVAC ANTIGEN ADJUVATED WITH ALUM
Common Name English
CORONAVAC ADJUVATED VACCINE ANTIGEN
Common Name English
SARS-COV-2 CN2 STRAIN .BETA.-PROPIOLACTONE INACTIVATED VACCINE ANTIGEN ADJUVATED WITH ALUM
Common Name English
Code System Code Type Description
FDA UNII
QU5NBP9XL3
Created by admin on Sat Jun 26 16:53:15 UTC 2021 , Edited by admin on Sat Jun 26 16:53:15 UTC 2021
PRIMARY
Related Record Type Details
TARGET ORGANISM->VACCINE ANTIGEN
On February 5, 2021 Sinovac announced data from a 12,396-participant, Phase III trial in Brazil and Turkey showing CoronaVac to be 100% effective in preventing death or hospitalization in patients with COVID-19, 83.7% effective in avoiding cases that required any medical treatment, but just 50.65% effective at preventing infection with the virus.
EFFICACY
Definition References